US20060217297A1 - Dimerized peptide - Google Patents
Dimerized peptide Download PDFInfo
- Publication number
- US20060217297A1 US20060217297A1 US10/541,821 US54182105A US2006217297A1 US 20060217297 A1 US20060217297 A1 US 20060217297A1 US 54182105 A US54182105 A US 54182105A US 2006217297 A1 US2006217297 A1 US 2006217297A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- seq
- leu
- amino acid
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OTMSDBZUPAUEDD-UHFFFAOYSA-N CC Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Definitions
- the present invention relates to cancer vaccine therapy, more particularly to a peptide dimer which can produce a tumor antigen peptide having activity of inducing cytotoxic T cells, and a pharmaceutical composition comprising the same.
- the cell mediated immunity particularly a cytotoxic T cell (hereinafter, referred to as “CTL”) plays a significant role in the in vivo rejection of tumor cells or virus-infected cells.
- CTLs recognize a complex between an antigen peptide (“tumor antigen peptide”) derived from a tumor antigen protein and an MHC (major histocompatibility complex) class I antigen, which is referred to as “HLA antigen” in the case of human, on a cancer cell, and attack and kill the cell.
- tumor antigen peptide an antigen peptide
- MHC major histocompatibility complex
- tumor antigen proteins include those listed in the Table of Immunity, vol. 10:281, 1999. Specific examples include the melanosome antigens such as melanocyte tissue-specific protein gp 100 (J. Exp. Med., 179: 1005, 1994), MART-1 (Proc. Natl. Acad. Sci. USA, 91:3515, 1994) and tyrosinase (J. Exp. Med., 178: 489, 1993), and tumor markers as antigen proteins other than melanoma such as HER2/neu (J. Exp. Med., 181: 2109, 1995), CEA (J. Natl. Cancer. Inst., 87:982, 1995) and PSA (J. Natl. Cancer. Inst., 89:293, 1997).
- melanosome antigens such as melanocyte tissue-specific protein gp 100 (J. Exp. Med., 179: 1005, 1994), MART-1 (Proc. Natl. Acad. Sci. USA, 91
- a tumor antigen peptide is a peptide of around 8 to 11 amino acids that can be produced by intracellular processing of a tumor antigen protein by a protease in cells (Cur. Opin, Immunol., 5: 709, 1993 ; Cur. Opin, Immunol., 5: 719, 1993; Cell, 82: 13, 1995 ; Immunol. Rev., 146: 167, 1995).
- the so produced tumor antigen peptide is presented on the surface of a cell as a complex with an MHC class I antigen (HLA antigen) and recognized by CTLs.
- HLA antigen MHC class I antigen
- cancer vaccine an immunotherapeutic agent for cancer (cancer vaccine) that makes use of the tumor cell destruction by CTLs, it is highly important to identify a tumor antigen peptide in a tumor antigen protein, which peptide is able to induce CTLs efficiently.
- One of purposes of the present invention is to provide a novel tumor antigen derived from a tumor antigen peptide useful in vivo.
- the present inventors have found that some peptides having been demonstrated to be a tumor antigen peptide contain a cysteine residue(s) and that a dimer composed of such peptides surprisingly show an activity of inducing CTLs (“CTL-inducing activity”) equivalent to the monomer upon administration, and established the present invention.
- CTL-inducing activity an activity of inducing CTLs
- the present invention encompasses the followings.
- a peptide dimer wherein two peptide monomers each consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide having CTL-inducing activity are bound each other through a disulfide bond(s).
- a pharmaceutical composition comprising a peptide dimer according to any one of (1) to (6) above together with a pharmaceutically acceptable carrier.
- a method of treating or preventing cancer which comprises administering a therapeutically effective amount of a peptide dimer according to any one of (1) to (6) above to a WT1-positive patient in need thereof.
- FIG. 1 is a graph showing that a peptide dimer (SEQ ID NO: 44) induces CTLs in transgenic mouse.
- two peptide monomers are dimerized through a disulfide bond(s) between SH groups of at least a pair of cysteine residues present in the peptide monomers.
- the peptide dimer of the present invention has a CTL-inducing activity and the CTLs thus induced can exert an antitumor activity through the cytotoxic effects or the production of lymphokines. Accordingly, the peptide dimer of the present invention can be used as a cancer vaccine for treatment or prevention of cancers (tumors).
- the peptide monomer constituting the peptide dimer of the present invention consists of 7-30 amino acid residues containing at least one cysteine residue, and produces a tumor antigen peptide having CTL-inducing activity.
- the phrase “produces a tumor antigen peptide” means that the peptide monomer has a characteristic of rendering a tumor antigen peptide capable of binding to an HLA antigen and being recognized by cytotoxic T cell (CTL).
- CTL cytotoxic T cell
- Any peptide monomer can be used in the present invention without limitation as far as it has a CTL-inducing activity; however, a peptide monomer which is derived from the tumor suppressor gene WT1 of human Wilms' tumor and comprises at least one cysteine residue is preferred.
- the tumor suppressor gene WT1 is expressed in various kinds of tumors (Cell, 60:509, 1990; NCBI data base Accession No. XP — 034418, SEQ ID NO: 1).
- the WT1 gene was isolated from chromosome 11p13 as one of the causative genes of Wilms' tumors based on the analysis of the WAGR syndrome that was complicated by Wilms' tumors, aniridia, urogenital anomaly, mental retardation, etc. (Nature, 343: 774, 1990).
- the genomic DNA of WT1 is about 50 kb, and is composed of ten exons, and of which the cDNA is about 3 kb.
- the amino acid sequence deduced from the cDNA is as shown in SEQ ID NO: 1 (Cell., 60:509, 1990).
- the WT1 gene has been suggested to promote the growth of leukemia cells from the facts that the WT1 gene is highly expressed in human leukemia, and that the leukemia cells are suppressed in their cellular growth by the treatment with WT1 antisense oligomers (JP-A-104627/1997). Then, the WT1 gene has been demonstrated to be a new tumor antigen protein of leukemia and solid cancers (J. Immunol., 164: 1873-80, 2000, and J. Clin.
- cancer immunotherapy is preferably applicable to as many cancer patients as possible, it is significant to identify tumor antigen peptides from WT1 which is highly expressed in many kinds of cancers, and to develop cancer vaccines using the resultant tumor antigen peptides.
- cancer vaccine is preferably applicable to as many cancer patients as possible, it is significant to identify tumor antigen peptides from WT1 which is highly expressed in many kinds of cancers, and to develop cancer vaccines using the resultant tumor antigen peptides.
- several natural-type tumor antigen peptides consisting of partial fragments of WT1 protein are described in WO00/06602 and WO00/18795; however, nothing has been known about their in vivo effects.
- peptide monomers usable in the present invention include tumor antigen peptides containing at least one cysteine residue which are derived from tumor antigen proteins listed in the Table of Immunity, vol. 10:281, 1999.
- the CTL-inducing activity can be confirmed by measuring the number of CTLs by HLA tetramer method (Int. J. Cancer: 100, 565-570 (2002)) or limiting dilution method (Nat. Med.:4, 321-327 (1998)).
- HLA-A24-restricted CTL-induction the activity can be determined using HLA-A24 model mouse according to the method described in WO02/47474 or Int. J. Cancer: 100, 565-570 (2002).
- the peptide monomer consists of 7-30, preferably 8-12, more preferably 9-11 amino acid residues.
- the peptide monomer preferably contains 1 or 2 cysteine resides taking into account both the motif for binding with HLA and the length of peptide.
- the peptide monomer can be synthesized according to a method generally used in the field of peptide chemistry. Such a method can be found in literatures including Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol. 2, Academic Press Inc., New York, 1976; Peptide Synthesis, Maruzen, Inc., 1975; Peptide-Gosei no Kiso to Jikken, Maruzen, Inc., 1985; and Iyakuhin no Kaihatsu (Zoku), Vol. 14, Peptide Synthesis, Hirokawa-syoten, 1991.
- the resultant peptide monomers can be allowed to form an intermolecular disulfide bond according to a method generally used in the peptide chemistry.
- the method for forming a disulfide bond can be found in literatures including Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol. 2, Academic Press Inc., New York, 1976; Peptide Synthesis, Maruzen, Inc., 1975; Peptide-Gosei no Kiso to Jikken, Maruzen, Inc., 1985; and Iyakuhin no Kaihatsu (Zoku), Vol. 14, Peptide Synthesis, Hirokawa-syoten, 1991.
- a peptide monomer containing one cysteine residue can be synthesized by, for example, removing all the protecting groups including the one on the cysteine side chain, and then subjecting the resulting monomer solution to air-oxidation under alkali condition, or forming a disulfide bond(s) by adding an oxidizing agent under alkali or acidic condition.
- oxidizing agent include iodine, dimethylsulfoxide (DMSO), potassium ferricyanide, and the like.
- a monomer peptide containing two or more cysteine residues can be also synthesized according to the method described above. In this case, isomers resulting from disulfide bonds of different binding manner can be obtained.
- a peptide dimer wherein a disulfide bond is formed between intended cysteine residues can be prepared by selecting a particular combination of protecting groups for cysteine side chains. Examples of the combination of protecting groups include MeBzl (methylbenzyl) and Acm (acetamidemethyl) groups, Trt (trityl) and Acm groups, Npys (3-nitro-2-pyridylthio) and Acm groups, S-Bu-t (S-tert-butyl) and Acm groups, and the like.
- the preparation can be carried out by a method comprising removing protecting groups other than MeBzl group and a protecting group(s) on the cysteine side chain, and subjecting the resulting monomer solution to air-oxidation to form a disulfide bond(s) between the deprotected cysteine residues, followed by deprotection and oxidization with iodine to form a disulfide bond(s) between the cysteine residues previously protected by Acm.
- the resultant peptide dimer can be purified according to processes generally used in the field of peptide chemistry. Such a purification method can be found in literatures including Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol. 2, Academic Press Inc., New York, 1976; Peptide Synthesis, Maruzen, Inc., 1975; Peptide-Gosei no Kiso to Jikken, Maruzen, Inc., 1985; and Iyakuhin no Kaihatsu (Zoku), Vol. 14, Peptide Synthesis, Hirokawa-syoten, 1991. A method using HPLC is preferred.
- the resultant peptide dimer of the present invention shows excellent stability against an oxidizing agent or the like in solution and possesses a given quality and CTL-inducing activity due to the disulfide bond(s) between cysteine residues.
- Preferred peptide monomers usable in the present invention are illustrated below taking WT1 as an example.
- Ala(A) alanine residue
- Arg(R) arginine residue
- Asn(N) asparagine residue
- Asp(D) aspartic acid residue
- Cys(C) cysteine residue
- Gln(Q) glutamine residue
- Glu(E) glutamic acid residue
- Gly(G) glycine residue
- His(H) histidine residue
- Ile(I) isoleucine residue
- Leu(L) leucine residue
- Lys(K) lysine residue
- Met(M) methionine residue
- Phe(F) phenylalanine residue
- Pro(P) proline residue
- Ser(S) serine residue
- Thr(T) threonine residue
- Trp(W) Trp(W):
- position refers to the position of the peptide in human WT1.
- HLA-A1-restricted Peptide Monomers Position Amino acid sequence SEQ ID NO: 137-145 CLESQPAIR 2 80-88 GAEPHEEQC 3 354-362 QCDFKDCER 4 409-417 TSEKPFSCR 5 386-394 KTCQRKFSR 6 325-333 CAYPGCNKR 7 232-240 QLECMTWNQ 8 317-325 TSEKRPFMC 9
- HLA-A68.1-restricted Peptide Monomers Position Amino acid sequence SEQ ID NO: 100-108 FTGTAGACR 26 386-394 KTCQRKFSR 6 409-417 TSEKPFSCR 5 325-333 CAYPGCNKR 7 354-362 QCDFKDCER 4 324-332 MCAYPGCNK 27 379-387 GVKPFQCKT 28 137-145 CLESQPAIR 2
- HLA-B4403-restricted Peptide Monomers Position Amino acid sequence SEQ ID NO: 349-357 GEKPYQCDF 37 84-92 HEEQCLSAF 42 410-418 SEKPFSCRW 34 278-286 TPILCGAQY 57 318-326 SEKRPFMCA 35 81-89 AEPHEEQCL 17 101-109 TGTAGACRY 50 85-93 EEQCLSAFT 38 233-241 LECMTWNQM 36 104-112 AGACRYGPF 63
- HLA-B5102-restricted Peptide Monomers Position Amino acid sequence SEQ ID NO: 130-138 NAPYLPSCL 20 20-28 GGGGCALPV 47 412-420 KPFSCRWPS 60 18-26 LGGGGGCAL 46 24-32 CALPVSGAA 66 136-144 SCLESQPAI 53 418-426 WPSCQKKFA 64 351-359 KPYQCDFKD 67
- the binding motif for HLA-A24 is known that, in the peptides consisting of 8 to 11 amino acid 10 residues, the amino acid at position 2 is tyrosine (Tyr), phenylalanine (Phe), methionine (Met) or tryptophan (Trp), and the amino acid at the C-terminus is phenylalanine (Phe), leucine (Leu), isoleucine (Ile), tryptophan (Trp) or methionine (Met) (J.
- a peptide monomer of the following formula can also be preferably used as an HLA-24-restricted peptide monomer.
- Xaa Thr Trp Asn Gln Met Asn Xaa (SEQ ID NO: 72) wherein Xaa at position 2 is an amino acid residue selected from Tyr, Phe, Met and Trp; and Xaa at position 9 is an amino acid residue selected from Phe, Leu, Ile, Trp and Met.
- the binding motif for HLA-A0201 is known that, in the peptides consisting of 8 to 11 amino acid residues, the amino acid at position 2 is leucine (Leu) or methionine (Met), and the amino acid at the C-terminus is valine (Val) or leucine (Leu).
- the binding motif for HLA-A0205 is known that, in the peptides consisting of 8 to 11 amino acid residues, the amino acid at position 2 is valine (Val), leucine (Leu), isoleucine(Ile) or methionine (Met) and the amino acid at the C terminus is leucine (Leu) (Immunogenetics, 41, p. 178, 1995; J. Immunol., 155: p.
- a peptide wherein the amino acid at position 2 or the C terminus of a peptide monomer shown in Table 2 or 3 above is substituted by any one of amino acid motifs described above can also be preferably used as an HLA-A0201-or HLA-A0205-restricted peptide monomer.
- the peptide monomers shown in Table 4 above are especially preferred to be used in the present invention.
- the SEQ ID NO:44 is a non-natural variant peptide wherein the methionine at position 236 of SEQ ID NO: 11 (position 235-243) is altered to tyrosine.
- the peptide monomers of the present invention include those having a sequence wherein one or more amino acid residues other than cysteine residue are altered in the sequence of natural-type peptides and showing CTL inducing activity.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a peptide dimer of the present invention together with a therapeutically acceptable carrier therefor.
- amount of a peptide dimer of the present invention as an active ingredient in the pharmaceutical composition may vary depending on the purpose of treatment, the age, weight of the patient, and the like, it is typically 0.0001 mg to 1000 mg, preferably 0.001 mg to 1000 mg, more preferably 0.1 mg to 20 mg.
- the pharmaceutical composition of the present invention may comprise, as an active ingredient, a peptide monomer in addition to a peptide dimer of the present invention.
- a “peptide dimer” in the pharmaceutical composition of the present invention can be 50% or more, preferably 70-100%, and more preferably 80-100% of the whole peptides.
- the content of a peptide dimer can be confirmed by high performance liquid chromatography (HPLC).
- the pharmaceutically acceptable carriers are those being capable of enhancing the cellular immunity.
- Such carriers include an adjuvant.
- adjuvant applicable to the present invention include those described in a literature (Clin. Microbiol. Rev., 7: 277-289, 1994), specifically, components derived from microorganisms, cytokines, components derived from plants, mineral gels such as aluminium hydroxide, lysolecithin, surfactants such as Pluronic® polyols, polyanion, peptide, oil emulsion (emulsion preparation) and the like.
- the carrier includes components required for the preparation of liposomal preparations, particulate preparations in which the ingredient is bound to beads having a diameter of several ⁇ m, preparations in which the ingredient is attached to lipids, and the like.
- Administration may be achieved, for example, intradermally, subcutaneously, intramuscularly, or intravenously.
- Preferred route is intradermal or subcutaneous administration that induces CTLs efficiently.
- the frequency or interval of administration can be adjusted appropriately depending on the disease to be treated or prevented, and individual difference; however, the administration is preferably carried out more than one times at an interval of once in a several days to several months.
- the pharmaceutical composition of the present invention comprising a peptide dimer consisting of peptide monomers derived from WT1
- the peptide is presented to an HLA antigen of antigen-presenting cells to form a complex.
- CTLs specific for the presented HLA antigen complex are then proliferated and destroy cancer cells, whereby cancer can be treated or prevented.
- the pharmaceutical composition of the present invention can be used to treat or prevent cancers associated by the elevated expression level of WT1 gene including blood cancers such as leukemia, myelodysplastic syndrome, multiple myeloma and malignant lymphoma, and solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, embryonal cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and ovarian cancer.
- blood cancers such as leukemia, myelodysplastic syndrome, multiple myeloma and malignant lymphoma
- solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, embryonal cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and ovarian cancer.
- the present invention provides a method for treating or preventing cancers by administering the pharmaceutical composition of the present invention to a WT1-positive patient.
- Fmoc-Leu-Alko-resin (wherein Alko is p-alkoxybenzyl alcohol) (12 g) (0.81 mmol/g, Watanabe Chemical Industries, Ltd.) was charged in a reaction vessel (500 ml, Type ACT90 solid phase synthesizer, Advanced ChemTech) and washed once with DMF or the like (Process 1). The resin was then treated with 25% Pip (piperidine) (3 minutes ⁇ 1, and 15 minutes ⁇ 1) to cleave the Fmoc group (Process 2), and washed again with DMF or the like (Process 1 ) to remove Pip.
- a reaction vessel 500 ml, Type ACT90 solid phase synthesizer, Advanced ChemTech
- Fmoc-Met-OH (18.27 g), Fmoc-Gln(Trt)-OH (30.04 g), Fmoc-Asn(Trt)-OH (29.36 g), Fmoc-Trp(Boc)-OH (25.91 g), Fmoc-Thr(tBu)-OH (19.56 g), Fmoc-Tyr(tBu)-OH (22.60 g) and Fmoc-Cys(Trt)-OH (28.82 g) were added in series to conduct the coupling reaction (Process 3), wherein the coupling was repeated three times with Fmoc-Thr(tBu)-OH.
- Air oxidization was conducted by stirring a mixture of a peptide monomer (227.5 mg) prepared in Preparation 1, N-methylglucamine (NMG) (227.5 mg) and water (23 ml) at room temperature for about 2 days.
- NMG N-methylglucamine
- To the reaction solution was added an aqueous solution of sodium acetate (2 g) in water (5 ml), and the mixture was stirred at room temperature for about 20 minutes.
- water (200 ml) and acetonitrile (ca. 200 ml) the mixture was filtered through Kiriyama Roht (filter paper No. 5C), and the residue on the filter was washed with water (ca. 50 ml ⁇ 3).
- the residue on the filter was collected and lyophilized after adding water (ca. 200 ml) to obtain the crude product of objective peptide dimer (158 mg).
- the CTL-inducing activity of the peptide dimer prepared in Example 1 was evaluated using HLA-A24 transgenic mice (Int. J. Cancer: 100, 565, 2002).
- the peptide dimer was dissolved in dimethyl sulfoxide (DMSO) to obtain a 40 mg/ml peptide solution.
- the peptide solution (35 ⁇ l) was then added to 10 mM phosphate buffer (pH 7.5) (581 ⁇ l) to obtain a peptide suspension.
- the resultant peptide suspension (550 ⁇ l) and Montanide ISA51 (Seppic) (700 ⁇ l) were mixed using a connected glass syringe to prepare an emulsion as an administration solution.
- the administration solution (200 ⁇ l) was injected into an HLA-A24 transgenic mouse subcutaneously in the base of the tail. Three mice were used. Seven days after the injection, the spleen was removed and splenocytes were prepared. A portion of the splenocytes was pulsed with the peptide dimer (100 ⁇ g/ml) for 1 hour. Splenocytes not pulsed with the peptide were seeded into a 24-well plate at 7 ⁇ 10 6 cells/well and thereto were added the above-mentioned splenocytes pulsed with the peptide (1 ⁇ 10 6 cells/well), and the plate was incubated.
- the incubation was conducted in RPMI1640 medium supplemented with 10% FCS, 10 mM HEPES, 20 mM L-glutamine, 1 mM sodium pyruvate, 1 mM MEM nonessential amino acids, 1% MEM vitamin and 55 ⁇ M 2-mercaptoethanol for 5 days.
- the cultured splenocytes were examined for the cytotoxic activity specific for the peptide used in the administration by 51 Cr release assay (J. Immunol.: 159, 4753, 1997).
- EL4-A2402/K b cells obtained by transforming EL-4 cells (ATCC No. TIB-39) in such a manner that a chimera MHC class I molecule of HLA-A24 and H2K b (Int. J. Cancer: 100, 565, 20002) are expressed stably were used as the target cells.
- the target cells were labeled with 51 Cr (3.7 MBq/10 6 cells) and pulsed with the peptide at 100 ⁇ g/ml for an hour.
- target cells not pulsed with the peptide were labeled with 51 Cr for 2 hours.
- Those labeled target cells and the previously prepared splenocytes were mixed at a ratio of 1:120, cultured for 4 hours and the CTL activity was evaluated on the basis of the percent of damaged target cells.
- the results are shown in FIG. 1 .
- the splenocytes prepared from the mouse injected with the peptide injured strongly the target cells pulsed with the peptide. However, they showed only weak cytotoxicity on the target cells not pulsed with the peptide. These results clearly showed that CTLs specific for the peptide were induced.
- a peptide dimer having a CTL-inducing activity in vivo and pharmaceutical compositions comprising the same as an active ingredient are provided.
- the present invention can be useful in the improvement of conditions of many tumor patients.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/795,187 US8242084B2 (en) | 2003-01-15 | 2010-06-07 | Dimerized peptide |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-007122 | 2003-01-15 | ||
JP2003007122 | 2003-01-15 | ||
PCT/JP2004/000254 WO2004063217A1 (fr) | 2003-01-15 | 2004-01-15 | Peptide dimerise |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/795,187 Continuation US8242084B2 (en) | 2003-01-15 | 2010-06-07 | Dimerized peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060217297A1 true US20060217297A1 (en) | 2006-09-28 |
Family
ID=32709100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/541,821 Abandoned US20060217297A1 (en) | 2003-01-15 | 2004-01-15 | Dimerized peptide |
US12/795,187 Expired - Lifetime US8242084B2 (en) | 2003-01-15 | 2010-06-07 | Dimerized peptide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/795,187 Expired - Lifetime US8242084B2 (en) | 2003-01-15 | 2010-06-07 | Dimerized peptide |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060217297A1 (fr) |
EP (2) | EP2154145B1 (fr) |
JP (2) | JP4498274B2 (fr) |
KR (2) | KR20120054644A (fr) |
CN (2) | CN1756763B (fr) |
AT (1) | ATE444969T1 (fr) |
AU (1) | AU2004204031B2 (fr) |
BR (1) | BRPI0406800B8 (fr) |
CA (1) | CA2513701C (fr) |
DE (1) | DE602004023476D1 (fr) |
ES (1) | ES2332590T3 (fr) |
HK (2) | HK1081975A1 (fr) |
WO (1) | WO2004063217A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143291A1 (en) * | 1998-07-31 | 2009-06-04 | International Institute Of Cancer Immunology, Inc. | Tumor antigen based on products of the tumor suppressor gene wt1 |
US20090263409A1 (en) * | 2002-09-12 | 2009-10-22 | International Institute Of Cancer Immunology, Inc | Cancer antigen peptide formulations |
US20090325886A1 (en) * | 2001-03-22 | 2009-12-31 | International Institute Of Cancer Immunology, Inc | Wt1 modified peptide |
US20100062010A1 (en) * | 2005-11-30 | 2010-03-11 | International Institute Of Cancer Immunology, Inc. | Novel peptide compound |
US20100062013A1 (en) * | 2004-03-31 | 2010-03-11 | International Institute Of Cancer Immunology, Inc. | Cancer antigen peptides derived from wt1 |
US20110098233A1 (en) * | 2006-12-28 | 2011-04-28 | Haruo Sugiyama | Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
US9181302B2 (en) | 2013-03-29 | 2015-11-10 | Sumitomo Dainippon Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
US9833493B2 (en) | 2012-12-17 | 2017-12-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
US10124046B2 (en) | 2003-11-05 | 2018-11-13 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US10139395B2 (en) | 2007-02-27 | 2018-11-27 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
US10471136B2 (en) | 2014-09-27 | 2019-11-12 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition for injection |
US10588952B2 (en) * | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
US10654892B2 (en) | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002097044A2 (fr) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Formes d'epissage alternatives de proteines servant de base pour modalites therapeutiques multiples |
RU2396088C2 (ru) * | 2005-02-04 | 2010-08-10 | СУРВАК АпС | Вакцина на основе пептидов сурвивина |
PL1988163T3 (pl) | 2006-02-22 | 2012-11-30 | Int Inst Cancer Immunology Inc | Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna |
ATE443722T1 (de) * | 2006-02-23 | 2009-10-15 | Fibrex Medical Res & Dev Gmbh | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung |
AU2008292913B2 (en) * | 2007-08-30 | 2014-06-05 | Curedm Group Holdings, Llc | Compositions and methods of using proislet peptides and analogs thereof |
NZ611176A (en) | 2010-12-02 | 2015-07-31 | Bionor Immuno As | Peptide scaffold design |
JP5893640B2 (ja) * | 2010-12-23 | 2016-03-23 | ファルネファ オーストリア ゲーエムベーハー | Oprf/i試薬と入院および他の患者におけるその利用 |
MX346475B (es) | 2011-01-06 | 2017-03-22 | Bionor Immuno As | Peptidos inmunogenicos monomericos y multimericos. |
WO2012105224A1 (fr) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | Adjuvant de vaccin |
ES2655031T3 (es) | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
EP3059242A4 (fr) | 2013-10-17 | 2017-04-19 | Seoul National University R&DB Foundation | Multimère de peptides de pénétration cellulaire à hélice alpha, procédé de préparation associé et utilisation associée |
JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
CN107921106B (zh) * | 2015-05-20 | 2023-09-08 | 住友制药株式会社 | Wt1抗原肽和免疫调节剂的组合用途 |
EP3322989A1 (fr) | 2015-07-14 | 2018-05-23 | Yeda Research and Development Co., Ltd. | Combinaisons de peptides à utiliser pour le diagnostic de la schizophrénie |
US20200368338A1 (en) * | 2017-12-27 | 2020-11-26 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate of wt1-derived peptides and composition comprising the same |
US20240207426A1 (en) * | 2022-12-22 | 2024-06-27 | Defence Therapeutics Inc. | Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6034235A (en) * | 1995-06-01 | 2000-03-07 | Tadamitsu Kishimoto | Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1) |
US20040097703A1 (en) * | 2001-03-22 | 2004-05-20 | Haruo Sugiyama | Wt1 modified peptide |
US20040247609A1 (en) * | 2001-09-28 | 2004-12-09 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
US20050002951A1 (en) * | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
US20050266014A1 (en) * | 1998-07-31 | 2005-12-01 | Haruo Sugiyama | Tumor antigen based on products of the tumor suppressor gene WT1 |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US20090099090A1 (en) * | 2002-06-12 | 2009-04-16 | Sumitomo Pharmaceuticals Company, Limited | Hla-a24-restricted cancer antigen peptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3060287B2 (ja) | 1995-10-09 | 2000-07-10 | 参天製薬株式会社 | アパファントを主薬とする水性点眼剤 |
CA2349442C (fr) * | 1998-09-30 | 2012-12-04 | Corixa Corporation | Compositions et methodes relatives a une immunotherapie specifique du wt1 |
GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
WO2002047474A1 (fr) | 2000-12-13 | 2002-06-20 | Sumitomo Pharmaceuticals Company, Limited | Animaux transgeniques exprimant hla-a24 et utilisation de ceux-ci |
KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
SI1731605T1 (sl) | 2004-03-31 | 2010-07-30 | Internat Inst Of Cancer Immunolog Inc | Peptidi antigena karcinoma izvedeni iz WT1 |
-
2004
- 2004-01-15 US US10/541,821 patent/US20060217297A1/en not_active Abandoned
- 2004-01-15 CA CA2513701A patent/CA2513701C/fr not_active Expired - Lifetime
- 2004-01-15 KR KR1020127008760A patent/KR20120054644A/ko not_active Application Discontinuation
- 2004-01-15 EP EP09172205.8A patent/EP2154145B1/fr not_active Expired - Lifetime
- 2004-01-15 AT AT04702444T patent/ATE444969T1/de not_active IP Right Cessation
- 2004-01-15 EP EP04702444A patent/EP1584627B1/fr not_active Expired - Lifetime
- 2004-01-15 ES ES04702444T patent/ES2332590T3/es not_active Expired - Lifetime
- 2004-01-15 DE DE602004023476T patent/DE602004023476D1/de not_active Expired - Lifetime
- 2004-01-15 CN CN2004800058473A patent/CN1756763B/zh not_active Expired - Lifetime
- 2004-01-15 KR KR1020057012761A patent/KR101399678B1/ko active IP Right Grant
- 2004-01-15 CN CN201010156098A patent/CN101851275A/zh active Pending
- 2004-01-15 JP JP2005508011A patent/JP4498274B2/ja not_active Expired - Lifetime
- 2004-01-15 BR BRPI0406800A patent/BRPI0406800B8/pt active IP Right Grant
- 2004-01-15 WO PCT/JP2004/000254 patent/WO2004063217A1/fr active Application Filing
- 2004-01-15 AU AU2004204031A patent/AU2004204031B2/en not_active Expired
-
2006
- 2006-02-23 HK HK06102442.4A patent/HK1081975A1/xx not_active IP Right Cessation
-
2009
- 2009-11-16 JP JP2009260957A patent/JP4926231B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-07 US US12/795,187 patent/US8242084B2/en not_active Expired - Lifetime
- 2010-08-16 HK HK10107803.0A patent/HK1141539A1/xx not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6034235A (en) * | 1995-06-01 | 2000-03-07 | Tadamitsu Kishimoto | Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1) |
US6277832B1 (en) * | 1995-06-01 | 2001-08-21 | Tadamitsu Kishimoto | Growth inhibitor for leukemia cells comprising antisense oligonucleotide derivative to wilms tumor gene (wt1) |
US20050266014A1 (en) * | 1998-07-31 | 2005-12-01 | Haruo Sugiyama | Tumor antigen based on products of the tumor suppressor gene WT1 |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US20040097703A1 (en) * | 2001-03-22 | 2004-05-20 | Haruo Sugiyama | Wt1 modified peptide |
US20040247609A1 (en) * | 2001-09-28 | 2004-12-09 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
US20050002951A1 (en) * | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
US20090099090A1 (en) * | 2002-06-12 | 2009-04-16 | Sumitomo Pharmaceuticals Company, Limited | Hla-a24-restricted cancer antigen peptides |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090281043A1 (en) * | 1998-07-31 | 2009-11-12 | International Institute Of Cancer Immunology, Inc. | Tumor antigen based on products of the tumor suppressor gene wt1 |
US7807792B2 (en) | 1998-07-31 | 2010-10-05 | International Institute Of Cancer Immunology, Inc. | Tumor antigen based on products of the tumor suppressor gene WT1 |
US9403886B2 (en) | 1998-07-31 | 2016-08-02 | International Institute Of Cancer Immunology, Inc. | Tumor antigen based on products of the tumor suppressor gene WT1 |
US20090143291A1 (en) * | 1998-07-31 | 2009-06-04 | International Institute Of Cancer Immunology, Inc. | Tumor antigen based on products of the tumor suppressor gene wt1 |
US20090325886A1 (en) * | 2001-03-22 | 2009-12-31 | International Institute Of Cancer Immunology, Inc | Wt1 modified peptide |
US8105604B2 (en) | 2001-03-22 | 2012-01-31 | International Institute Of Cancer Immunology, Inc. | WT1 modified peptide |
US20090263409A1 (en) * | 2002-09-12 | 2009-10-22 | International Institute Of Cancer Immunology, Inc | Cancer antigen peptide formulations |
US11027003B2 (en) | 2003-11-05 | 2021-06-08 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US10124046B2 (en) | 2003-11-05 | 2018-11-13 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US8388975B2 (en) | 2004-03-31 | 2013-03-05 | International Institute Of Cancer Immunology, Inc. | Cancer antigen peptides derived from WT1 |
US20100062013A1 (en) * | 2004-03-31 | 2010-03-11 | International Institute Of Cancer Immunology, Inc. | Cancer antigen peptides derived from wt1 |
US20110229506A1 (en) * | 2005-11-30 | 2011-09-22 | International Institute Of Cancer Immunology, Inc. | Method for cancer immunotherapy |
US8575308B2 (en) | 2005-11-30 | 2013-11-05 | International Institute of Cancer Immunology | Method for cancer immunotherapy |
US20100062010A1 (en) * | 2005-11-30 | 2010-03-11 | International Institute Of Cancer Immunology, Inc. | Novel peptide compound |
US9273148B2 (en) | 2005-11-30 | 2016-03-01 | International Institute Of Cancer Immunology, Inc. | Method for cancer immunotherapy |
US7939627B2 (en) * | 2005-11-30 | 2011-05-10 | International Institute of Cancer Immunology | Peptides comprising an epitope of the wilms tumor gene product |
US9765114B2 (en) | 2005-11-30 | 2017-09-19 | International Institute Of Cancer Immunology, Inc. | Method for cancer immunotherapy |
TWI554280B (zh) * | 2006-12-28 | 2016-10-21 | 癌免疫研究所股份有限公司 | Hla-a*1101限制性wt1胜肽之用途 |
TWI417103B (zh) * | 2006-12-28 | 2013-12-01 | Int Inst Cancer Immunology Inc | Hla-a*1101限制性wt1胜肽及含有該限制性胜肽之醫藥組成物 |
US8653038B2 (en) * | 2006-12-28 | 2014-02-18 | International Institute Of Cancer Immunology, Inc. | HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same |
US20110098233A1 (en) * | 2006-12-28 | 2011-04-28 | Haruo Sugiyama | Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
AU2007340679B2 (en) * | 2006-12-28 | 2013-09-12 | International Institute Of Cancer Immunology, Inc. | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same |
US9272026B2 (en) | 2006-12-28 | 2016-03-01 | International Institute Of Cancer Immunology, Inc. | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same |
US11555814B2 (en) | 2007-02-27 | 2023-01-17 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper t cell and composition for use in the method |
US10139395B2 (en) | 2007-02-27 | 2018-11-27 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
US10654892B2 (en) | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
US9833493B2 (en) | 2012-12-17 | 2017-12-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
CN105308063A (zh) * | 2013-03-29 | 2016-02-03 | 大日本住友制药株式会社 | Wt1抗原肽缀合物疫苗 |
EP3461493A1 (fr) * | 2013-03-29 | 2019-04-03 | Sumitomo Dainippon Pharma Co., Ltd. | Vaccin conjugué de peptide d'antigène wt1 |
TWI666026B (zh) * | 2013-03-29 | 2019-07-21 | 日商大日本住友製藥股份有限公司 | Wt1抗原胜肽結合疫苗 |
US10588952B2 (en) * | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
EP2982681A4 (fr) * | 2013-03-29 | 2016-10-19 | Sumitomo Dainippon Pharma Co Ltd | Vaccin conjugué de peptide d'antigène wt1 |
US9248173B2 (en) | 2013-03-29 | 2016-02-02 | Sumitomo Dainippon Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
US9181302B2 (en) | 2013-03-29 | 2015-11-10 | Sumitomo Dainippon Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
US11759509B2 (en) * | 2013-03-29 | 2023-09-19 | Sumitomo Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
US10471136B2 (en) | 2014-09-27 | 2019-11-12 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition for injection |
Also Published As
Publication number | Publication date |
---|---|
JP4926231B2 (ja) | 2012-05-09 |
EP1584627A4 (fr) | 2006-03-15 |
CN101851275A (zh) | 2010-10-06 |
AU2004204031B2 (en) | 2010-03-04 |
KR20120054644A (ko) | 2012-05-30 |
JPWO2004063217A1 (ja) | 2006-06-01 |
KR101399678B1 (ko) | 2014-05-27 |
HK1141539A1 (en) | 2010-11-12 |
BRPI0406800B8 (pt) | 2021-05-25 |
ES2332590T3 (es) | 2010-02-09 |
CN1756763B (zh) | 2010-05-26 |
US20100292164A1 (en) | 2010-11-18 |
JP2010047603A (ja) | 2010-03-04 |
HK1081975A1 (en) | 2006-05-26 |
DE602004023476D1 (de) | 2009-11-19 |
WO2004063217A1 (fr) | 2004-07-29 |
EP2154145A3 (fr) | 2010-05-19 |
CA2513701C (fr) | 2013-06-18 |
EP2154145A2 (fr) | 2010-02-17 |
CN1756763A (zh) | 2006-04-05 |
BRPI0406800A8 (pt) | 2016-11-01 |
US8242084B2 (en) | 2012-08-14 |
AU2004204031A1 (en) | 2004-07-29 |
BRPI0406800A (pt) | 2006-01-17 |
KR20050098863A (ko) | 2005-10-12 |
ATE444969T1 (de) | 2009-10-15 |
CA2513701A1 (fr) | 2004-07-29 |
EP1584627A1 (fr) | 2005-10-12 |
BRPI0406800B1 (pt) | 2020-08-11 |
EP2154145B1 (fr) | 2013-04-24 |
EP1584627B1 (fr) | 2009-10-07 |
JP4498274B2 (ja) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8242084B2 (en) | Dimerized peptide | |
US11759509B2 (en) | WT1 antigen peptide conjugate vaccine | |
CA3058567A1 (fr) | Vaccin pcsk9 a base de nouveaux peptides | |
US20220098256A1 (en) | Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUGIYAMA, HARUO, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUGIYAMA, HARUO;TAKASU, HIDEO;SAMIZO, FUMIO;REEL/FRAME:017576/0994;SIGNING DATES FROM 20050609 TO 20050610 Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUGIYAMA, HARUO;TAKASU, HIDEO;SAMIZO, FUMIO;REEL/FRAME:017576/0994;SIGNING DATES FROM 20050609 TO 20050610 Owner name: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUGIYAMA, HARUO;TAKASU, HIDEO;SAMIZO, FUMIO;REEL/FRAME:017576/0994;SIGNING DATES FROM 20050609 TO 20050610 |
|
AS | Assignment |
Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., JAPAN Free format text: MERGER;ASSIGNOR:SUMITOMO PHARMACEUTICALS COMPANY, LIMITED;REEL/FRAME:017149/0949 Effective date: 20051003 |
|
AS | Assignment |
Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUGIYAMA, HARUO;REEL/FRAME:018192/0210 Effective date: 20060806 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |